Quantitative studies of phagocytosis by means of thorotrast

Kabisch, William T.

doi:10.1002/ar.1091280308

Cited by 6 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Shwartzman reaction follows a two-step process, first sensitization and then provocation. The first step is thought to cause suppression of the RES, and thorotrast injection has been shown in animals to suppress the RES and bring about the preparatory sensitization needed for the Shwartzman reaction (7,10,11,28). Thorotrast-injected patients are thought to be in a kind of Shwartzman preparatory state due to chronic suppression of the RES following thorotrast administration.…”

Section: Thorotrastosis and Disseminated Intravascular Coagulationmentioning

confidence: 99%

Delayed Effect of Thorotrast Deposition in Humans: Carcinogenesis and Suppression of the Reticuloendothelial System

Irie

2000

Bioscience Microflora

View full text Add to dashboard Cite

Thorotrast is a colloidal solution containing 20% thorium (232Th), and used to be used primarily in diagnostic radiology for visualization. Once thorotrast is infused into the body, it is not eliminated easily. Over 90% of thorotrast forms deposits. It emits a-rays, and thorotrast-injected patients are semipermanently irradiated from a-particles deposited in the body. Thorotrast gives rise to malignant tumors by delayed effect of deposition, and especially liver cancer is highly associated with thorotrastosis. Deposition of thorotrast as an exogenous substance inhibits phagocytosis by suppressing the reticuloendothelial system (RES) as well and bringing about a Shwartzman preparatory state (preshock state) in patients. A majority of thorotrast-injected patients died abruptly. This short natural history of thorotrastosis is thought to have some relation to RES suppression by long-term thorotrast deposition resulting in vulnerability to shock and infection.

show abstract

Section: Thorotrastosis and Disseminated Intravascular Coagulationmentioning

confidence: 99%

Delayed Effect of Thorotrast Deposition in Humans: Carcinogenesis and Suppression of the Reticuloendothelial System

Irie

2000

Bioscience Microflora

View full text Add to dashboard Cite

show abstract

Quantitative characteristics of phagocytic organs

1968

View full text Add to dashboard Cite

Organ and tissue phagocytosis of intravenously injected cobaltic oxide was studied quantitatively over a wide range of dose levels by means of radioassay of Coz6003 in rats.There is a single linear relationship between the amount of particulate administered and the amount recovered from liver, spleen, and lung combined. The same is true for the uptake by the liver alone. However, the spleen and lung each has two linear relationships. For the spleen the two different linear trends are related to the dose administered, while for the lung the determining parameter is the weight and (or) age of the animal. Notwithstanding these different linear trends, the uptake by spleen and lung is interdependent.Although the liver is the main phagocytic organ, per unit weight the phagocytic uptake of the spleen exceeds that of the liver at amounts of cobaltic oxide larger than 40 mg. The reverse is true for amounts less than or equal to 40 mg.The phagocytic uptake by other components of the RES was not sufficient for reliable quantitative estimation.

show abstract

Systematic review of thorotrast data and facts: Animal experiments

Wegener

1979

Virchows Arch. A Path. Anat. and Histol.

View full text Add to dashboard Cite

Quantitative studies of phagocytosis by means of thorotrast

Cited by 6 publications

References 9 publications

Delayed Effect of Thorotrast Deposition in Humans: Carcinogenesis and Suppression of the Reticuloendothelial System

Delayed Effect of Thorotrast Deposition in Humans: Carcinogenesis and Suppression of the Reticuloendothelial System

Quantitative characteristics of phagocytic organs

Systematic review of thorotrast data and facts: Animal experiments

Contact Info

Product

Resources

About